Buyer’s Guide
7 Best EDC Platforms for FDA-Regulated Clinical Trials in the US (2026)
The seven EDC platforms to consider for FDA-regulated clinical trials in the US in 2026 are Clinion EDC, Viedoc, Medidata Rave EDC, Oracle Clinical One, Castor EDC, Medrio EDC, and Veeva Vault EDC. Beyond core data management capabilities, sponsors and CROs should evaluate 21 CFR Part 11 controls, system validation, audit trails, electronic signatures, inspection readiness, and alignment with ICH E6(R3) Good Clinical Practice.
Selecting EDC software for FDA-regulated clinical trials requires careful consideration of both clinical data management capabilities and regulatory requirements. The FDA’s October 2024 guidance on electronic systems, records, and signatures provides recommendations on maintaining trustworthy and reliable electronic trial records.
The FDA’s final ICH E6(R3) Good Clinical Practice guidance, issued in September 2025, further emphasises risk-based quality management, reliable trial results, and appropriate use of technology.
For US sponsors and CROs, choosing an EDC platform therefore involves evaluating study configuration, data review, integrations, and operational efficiency alongside validation documentation, electronic-record controls, and inspection readiness.
This guide compares seven EDC platforms to help clinical trial teams identify solutions suited to their regulatory, technical, and operational requirements.
Quick Comparison of the 7 Best EDC Platforms for FDA-Regulated Clinical Trials
Best For
Key Differentiators
How We Selected These EDC Platforms
We reviewed official product documentation, regulatory and security disclosures, and available independent user feedback. The comparison considers core EDC capabilities, integrations, validation support, and suitability for FDA-regulated clinical trials, including electronic-record controls and inspection readiness.
These platforms are presented for comparison, not as a numerical ranking.
Detailed Reviews of the 7 Best EDC Platforms for FDA-Regulated Clinical Trials in the US (2026)
The following reviews examine each platform’s core capabilities, differentiating features, and suitability for FDA-regulated clinical trials. They also consider electronic-record controls, validation support, and inspection readiness to help US sponsors and CROs evaluate the right platform for their studies.
1. Clinion EDC
Clinion EDC combines codeless study configuration, AI-assisted clinical data management, and a connected eClinical ecosystem. Its CDASH-aligned Global Library supports reusable study designs, while controlled mid-study amendments allow teams to update live studies without planned downtime.
A key differentiator is Clinion’s use of AI across multiple clinical data workflows, including study building, CDASH mapping, source-to-CRF conversion, medical coding, discrepancy detection, and reporting. Its Agentic Assistant enables natural-language access to protocol information, clinical data, and study operations. Clinion also offers AI-assisted remote SDV and Audit Trail Review capabilities, extending support beyond traditional EDC data capture.
Key features
- Codeless study configuration with reusable CDASH-aligned libraries and controlled amendments.
- AI-assisted study build, data review, medical coding, source-data workflows, and natural-language reporting.
- Agentic Assistant and integration across EDC, CTMS, RTSM, ePRO, eConsent, eSource, and eTMF.
FDA regulatory and compliance relevance
Clinion documents support for FDA 21 CFR Part 11, ICH GCP, and GAMP 5 principles, alongside ISO 27001 and ISO 9001 certifications. Its role-based access controls, audit trails, electronic-record management, and controlled study changes provide capabilities relevant to FDA data integrity and computerised system validation expectations. Clinion also reports experience supporting 150+ FDA studies.
Considerations
Sponsors should evaluate the validation evidence, electronic signature workflows, audit-trail records, and human oversight controls applicable to their studies, particularly when using AI-assisted functionality.
Pricing: Study-based pricing; available on request.
What Clinion EDC Users Say
2. Viedoc
Viedoc is a configurable EDC platform designed to give clinical data teams greater control over study setup and ongoing changes. Viedoc Designer supports reusable eCRFs, edit checks, study workflows, and multiple concurrent study versions, enabling amendments without traditional data migration or planned downtime.
Viedoc also supports query management, reporting, API connectivity, and AI-assisted medical coding. Its Viedoc Inspection Readiness Packet (VIRP) provides customers with release-specific validation documentation and information to support audits and regulatory inspections.
Key features
- Self-service study design with reusable components, configurable edit checks, and optional JavaScript for complex logic.
- Concurrent study versions and controlled protocol amendments without downtime.
- AI-assisted medical coding and an Inspection Readiness Packet containing validation documentation.
FDA regulatory and compliance relevance
Viedoc documents audit trails, electronic-record controls, and validation processes relevant to 21 CFR Part 11. Its Inspection Readiness Packet includes supplier documentation that supports assessments against the FDA’s guidance on electronic systems, records, and signatures in clinical investigations.
Considerations
Complex configurations may require JavaScript expertise. Buyers should confirm the availability of specific AI capabilities and assess study-level validation, electronic signatures, and data export requirements.
Pricing: Available on request.
What Viedoc Users Say
G2 Rating: 4.5/5 | Read Viedoc Reviews on G2
3. Medidata Rave EDC
Medidata Rave EDC is an enterprise clinical data management platform widely used in complex, multisite, and multinational trials. It supports standardised study configuration, edit checks, protocol amendments, and integration across Medidata’s broader clinical technology ecosystem.
Its differentiators include AI-assisted study configuration through Medidata Designer and Clinical Data Studio, which consolidates EDC and external datasets for cross-source reconciliation, anomaly detection, and centralised data review. Medidata also offers Rave Lite, a streamlined option designed for less complex studies, including early- and late-stage medical device trials.
Key features
- Enterprise EDC configuration with reusable standards, edit checks, and controlled amendments.
- Clinical Data Studio for multi-source data review, reconciliation, and AI-assisted anomaly detection.
- Broad integrations with RTSM, eCOA, clinical coding, and other data sources, alongside Rave Lite for selected study types.
FDA regulatory and compliance relevance
Medidata provides electronic-record controls, audit trails, electronic signature functionality, and supplier quality documentation relevant to FDA-regulated studies. Its established experience supporting global clinical trials and regulatory submissions makes it particularly relevant to sponsors with complex data management and inspection-readiness requirements.
Considerations
Enterprise implementations may involve specialist configuration resources and higher operational complexity. Buyers should evaluate the total cost of ownership, validation responsibilities, and whether Rave EDC or Rave Lite better fits their study requirements.
Pricing: Available on request.
What Medidata Rave EDC Users Say
G2 Rating: 4.7/5 | Read Medidata Rave EDC Reviews on G2
4. Oracle Clinical One
Oracle Clinical One is an enterprise clinical trial platform that combines electronic data capture, randomisation, and trial supply management. It is particularly relevant to FDA-regulated studies where subject data, treatment allocation, and investigational product supply must be coordinated across multiple sites.
A key differentiator is Advanced Study Versioning, which supports controlled changes to study designs, including certain updates to existing visits and forms. Oracle also provides Product Verification Packs (PVPs) containing release-specific testing evidence and traceability documentation.
Key features
- Advanced Study Versioning for managing protocol amendments in active trials.
- Integrated EDC, randomisation, and trial supply management workflows.
- Product Verification Packs with requirements, testing evidence, and traceability matrices.
FDA regulatory and compliance relevance
Oracle’s Product Verification Packs provide supplier documentation that can support sponsors’ computerised system validation and change-control assessments. Controlled study versioning, electronic records, and auditability are relevant to FDA 21 CFR Part 11 and GCP expectations.
Considerations
Implementation may involve specialist configuration and integration resources. Sponsors should review amendment dependencies, particularly where Clinical One connects with Oracle Data Management Workbench or other external systems.
Pricing: Available on request.
What Oracle Clinical Users Say
G2 Rating: 4.1/5 | Read Oracle Clinical Reviews on G2
Note: This rating and feedback relate to Oracle Clinical, not specifically Oracle Clinical One.
5. Castor EDC
Castor EDC provides configurable electronic data capture alongside eCOA/ePRO and eConsent capabilities. Its no-code study builder supports electronic forms, validation rules, and clinical data collection across traditional, hybrid, and decentralised clinical trials.
Its differentiator is Castor Catalyst, an AI-assisted solution that extracts structured clinical data from EHR records and source documents. Each extracted value is presented for human verification before submission to the clinical database, reducing manual transcription while preserving reviewer oversight.
Key features
- No-code study configuration with edit checks and query management.
- Castor Catalyst for AI-assisted source-data extraction and human verification.
- Connected eConsent, eCOA/ePRO, and support for decentralised research workflows.
FDA regulatory and compliance relevance
Castor documents controls supporting 21 CFR Part 11, including time-stamped audit trails, electronic signatures, role-based permissions, and data export capabilities. Its validation programme follows GAMP 5 principles under ISO 9001 and ISO 27001 management systems.
Considerations
Confirm which capabilities are included in core EDC and which require additional products or fees. Sponsors should also assess how AI-extracted data is reviewed, traced to its source, and validated for their intended use.
Pricing: Available on request.
What Castor EDC Users Say
G2 Rating: 4.6/5 | Read Castor Reviews on G2
6. Medrio EDC
Medrio EDC is a cloud-based clinical data capture platform suited to sponsors and CROs seeking flexible study configuration with limited programming requirements. Its point-and-click builder supports reusable study components, edit checks, skip logic, and self-service protocol amendments.
A distinctive capability is its always-available testing environment, which allows study teams to configure and evaluate changes separately from production. Medrio also provides connected eCOA, eConsent, and RTSM applications, supporting data collection across clinical trial workflows.
Key features
- No-code study configuration with reusable forms, edit checks, and skip logic.
- Separate testing environment for evaluating study changes before deployment.
- Self-service protocol amendments and integration with eCOA, eConsent, and RTSM.
FDA regulatory and compliance relevance
Medrio provides audit trails, electronic-record controls, access permissions, and validation support relevant to FDA-regulated research. Its separate testing environment can help sponsors document user acceptance testing and verify that study configurations operate as intended.
Considerations
Buyers should evaluate the platform’s suitability for highly complex studies, the depth of its advanced data review capabilities, and the integration and support services included in their agreement.
Pricing: Available on request.
What Medrio EDC Users Say
G2 Rating: 4.2/5 | Read Medrio Reviews on G2
7. Veeva Vault EDC
Veeva Vault EDC is part of the broader Vault Clinical ecosystem, connecting electronic data capture with clinical operations and data management applications. It is particularly relevant to sponsors seeking standardised clinical technology across multiple studies and functions.
Its differentiators include integration with Veeva Data Quality System (DQS) for reviewing EDC and external clinical datasets, configurable study design, and protocol amendments without planned downtime. Veeva also provides release-validation documentation that supports quality teams assessing system updates.
Key features
- Configurable study builds, automated validation rules, and controlled amendments.
- Multi-source clinical data review and reconciliation through Veeva DQS.
- Integration across Vault Clinical applications with structured release-validation documentation.
FDA regulatory and compliance relevance
Veeva provides validation documentation covering system requirements, qualification testing, and release impact assessments. These materials, alongside audit trails and controlled study configuration, can support sponsor evaluations under 21 CFR Part 11 and FDA GCP expectations.
Considerations
The platform may deliver the greatest benefit to organisations already adopting the Vault ecosystem. Veeva announced an AI-powered Study Builder Agent in September 2026, but early-adopter availability is planned for December 2026; buyers should distinguish announced capabilities from those currently available.
Pricing: Available on request.
What Veeva Vault Users Say
G2 Rating: 4.1/5 | Read Veeva Vault Reviews on G2
Note: This rating and feedback relate to the broader Veeva Vault platform, not specifically Veeva Vault EDC.
What Should US Sponsors and CROs Consider When Selecting EDC Software?
Choosing an EDC platform for an FDA-regulated study involves more than comparing data capture features. Sponsors and CROs need to understand how a system supports trustworthy electronic records, documented validation, clinical data quality, and efficient trial operations.
The following six factors should guide the evaluation.
1. FDA 21 CFR Part 11 and Electronic Record Controls
21 CFR Part 11 establishes requirements for electronic records and electronic signatures within its applicable scope. The FDA’s October 2024 guidance also provides recommendations on using electronic systems in clinical investigations.
When evaluating EDC software, confirm that the platform supports:
- Secure, time-stamped audit trails recording data creation and changes.
- Unique user identification and role-based access controls.
- Electronic signature workflows, where required.
- Accurate and accessible copies of electronic records.
- Documented system testing, validation, and change control.
Important: A vendor’s claim of Part 11 compliance does not automatically establish compliance for a sponsor’s specific study configuration and intended use.
2. Computerised System Validation and Inspection Readiness
The FDA’s final ICH E6(R3) Good Clinical Practice guidance, issued in September 2025, emphasises proportionate quality management and reliable clinical trial data.
Evaluate what evidence vendors provide to demonstrate that their systems have been tested and are fit for their intended purpose.
This may include validation plans, requirements traceability, qualification documentation, release testing records, and change-control procedures.
Ask how the system preserves audit trails and supports inspection access throughout the study lifecycle, including after database lock.
3. Study Configuration and Protocol Amendments
Clinical studies often require modifications after initial deployment. An EDC platform should enable teams to introduce those changes while preserving previously collected data and the history of study configurations.
Compare how vendors handle eCRF modifications, new visits, edit-check updates, version control, testing, and approval workflows.
Where possible, request a demonstration of a live-study amendment rather than relying solely on product documentation.
4. AI-Assisted Data Review and Human Oversight
AI capabilities now extend beyond basic data validation into discrepancy detection, medical coding, source-data extraction, audit-trail analysis, and natural-language reporting.
However, these capabilities differ significantly between vendors.
Assess the specific tasks performed by AI, whether it operates on live clinical data, how recommendations are verified, and whether decisions and outputs remain traceable.
For FDA-regulated studies, AI should support controlled clinical data management processes rather than introduce unverified changes to regulated records.
5. Clinical System Integration and Data Standards
EDC software frequently needs to exchange information with RTSM, CTMS, eCOA, eConsent, laboratories, imaging repositories, and safety systems.
Evaluate whether these connections are native or require custom interfaces, and how the platform handles failed transfers, duplicate records, updates, and reconciliation.
Also confirm support for relevant CDISC standards, including CDASH for collection design and appropriate export or transformation workflows supporting SDTM submission preparation.
6. Implementation, Support, and Total Cost
The overall cost of EDC extends beyond the initial licence.
Sponsors should assess study build, validation, training, protocol amendments, integrations, reporting, support, data extraction, and archive-related costs.
Compare how much work internal clinical data management teams can perform independently and where vendor or specialist services remain necessary.
The best-value platform is not necessarily the least expensive. It is the one that provides an appropriate balance of clinical functionality, regulatory controls, implementation effort, and long-term operating costs.
What Questions Should You Ask EDC Vendors Before Selecting a Platform?
A useful demonstration should show how the platform performs in a realistic FDA-regulated study scenario, including an amendment and an inspection-related request.
Practical tip: Ask every shortlisted vendor to demonstrate the same protocol scenario. This provides a more reliable comparison than reviewing different product demonstrations.
Choosing the Right EDC Platform for FDA-Regulated Trials
Choosing the right EDC platform for FDA-regulated clinical trials involves balancing regulatory requirements with study complexity, data management capabilities, and operational efficiency. While all seven platforms offer distinct strengths, sponsors and CROs should prioritise solutions that support 21 CFR Part 11 requirements, appropriate system validation, data integrity, and inspection readiness.
The final decision should be based on how effectively each platform supports your study workflows, integrates with existing clinical systems, and enables reliable data management throughout the trial lifecycle.
Why Clinion EDC Is the Best Choice for FDA-Regulated Clinical Trials in the US?
For US sponsors and CROs, managing FDA-regulated trials requires more than reliable data capture. It requires technology that can accelerate study execution, reduce manual effort, and support regulatory oversight without adding operational complexity. Clinion EDC combines codeless study configuration, AI-assisted data management, and connected eClinical workflows. Its reusable Global Library helps accelerate study setup, while controlled protocol amendments support zero planned study downtime.
With experience spanning 650+ clinical trials, including 150+ FDA studies, and 300,000+ patients, Clinion brings practical clinical research experience alongside its AI capabilities. Clinion reports 40–50% savings in total data management costs, 50% lower operational study-build costs, and an average go-live timeline of 2–4 weeks, helping sponsors and CROs improve efficiency without compromising the controls needed for regulated studies.
Request a Clinion EDC Demo to explore how Clinion can accelerate your next FDA-regulated clinical trial.
— FAQ's
Frequently Asked Questions About EDC Software for FDA-Regulated Clinical Trials
The best EDC platforms for FDA-regulated clinical trials in the US include Clinion EDC, Viedoc, Medidata Rave EDC, Oracle Clinical One, Castor EDC, Medrio EDC, and Veeva Vault EDC. These platforms offer different strengths in AI-assisted data management, study configuration, regulatory controls, validation support, and enterprise clinical trial management.
No, the FDA does not certify EDC software as 21 CFR Part 11 compliant. Sponsors and CROs are responsible for assessing applicable electronic-record controls, system validation, and operational procedures to ensure compliance for their intended use.
An EDC vendor should provide software requirements, validation summaries, qualification and testing records, traceability matrices, release notes, and change-control documentation. Sponsors should also verify whether additional validation is required for study-specific configurations and integrations.
Yes, AI can be used in FDA-regulated clinical data management for discrepancy detection, medical coding, source-data extraction, and reporting. AI-assisted workflows should be appropriately validated, with human oversight, traceable outputs, and controls to protect clinical data integrity.
Yes, ICH E6(R3) is relevant to EDC software selection in the US because it addresses clinical trial quality management, data reliability, and the appropriate use of technology. Sponsors should evaluate EDC validation, audit trails, access controls, and data oversight capabilities against these principles.
The main difference is that EDC software focuses on capturing clinical trial data through electronic case report forms, while a clinical data management system (CDMS) supports the broader data management lifecycle. CDMS workflows may include data cleaning, query management, medical coding, reconciliation, reporting, and database lock.
US sponsors should choose an integrated eClinical platform when they need connected workflows across EDC, RTSM, eCOA, eConsent, and other systems. Standalone EDC may be preferable when existing specialised applications already meet study requirements and can be integrated efficiently. The decision should consider operational complexity, validation effort, and total cost of ownership.
Unlock the Future of Clinical Trials with Clinion.
Cut your trial costs by 35% and accelerate your time-to-market by 30%